HomeCompareSCPH vs NOBL

SCPH vs NOBL: Dividend Comparison 2026

SCPH yields 35.27% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCPH wins by $155.7K in total portfolio value
10 years
SCPH
SCPH
● Live price
35.27%
Share price
$5.67
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.6K
Annual income
$27,157.20
Full SCPH calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — SCPH vs NOBL

📍 SCPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCPHNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCPH + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCPH pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCPH
Annual income on $10K today (after 15% tax)
$2,998.24/yr
After 10yr DRIP, annual income (after tax)
$23,083.62/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, SCPH beats the other by $22,871.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCPH + NOBL for your $10,000?

SCPH: 50%NOBL: 50%
100% NOBL50/50100% SCPH
Portfolio after 10yr
$100.7K
Annual income
$13,703.49/yr
Blended yield
13.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SCPH right now

SCPH
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Price Target
$8.12
+43.2% upside vs current
Range: $5.35 — $13.00
Altman Z
-7.3
Piotroski
2/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCPH buys
0
NOBL buys
0
No recent congressional trades found for SCPH or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCPHNOBL
Forward yield35.27%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$178.6K$22.9K
Annual income after 10y$27,157.20$249.78
Total dividends collected$129.2K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SCPH vs NOBL ($10,000, DRIP)

YearSCPH PortfolioSCPH Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$14,227$3,527.34$10,917$217.08+$3.3KSCPH
2$19,913$4,690.15$11,903$221.48+$8.0KSCPH
3$27,442$6,135.14$12,962$225.68+$14.5KSCPH
4$37,265$7,901.67$14,099$229.68+$23.2KSCPH
5$49,902$10,028.00$15,319$233.49+$34.6KSCPH
6$65,945$12,549.99$16,628$237.10+$49.3KSCPH
7$86,061$15,499.75$18,033$240.53+$68.0KSCPH
8$110,989$18,904.51$19,539$243.78+$91.5KSCPH
9$141,544$22,785.49$21,154$246.86+$120.4KSCPH
10$178,609$27,157.20$22,884$249.78+$155.7KSCPH

SCPH vs NOBL: Complete Analysis 2026

SCPHStock

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Full SCPH Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this SCPH vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCPH vs SCHDSCPH vs JEPISCPH vs OSCPH vs KOSCPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.